Latest news with #MitsuiFudosan
Yahoo
a day ago
- Business
- Yahoo
Construction and Real Estate Sponsorship of Sport Analysis Report 2025: Wanda Group Accounts for the Largest Partnership, Mitsui Fudosan Emerges as the Most Active with 11 Partnerships
Discover the 2025 Sponsorship Sector Report highlighting the global construction & real estate industry's impact on sports. Soccer leads with 60% of deal volume, with FIFA's Wanda Group deal topping the list. Mitsui Fudosan and Wanda Group are top investors. Explore major deals and brand activities worldwide. Dublin, June 04, 2025 (GLOBE NEWSWIRE) -- The "Sponsorship Sector Report - Construction & Real Estate 2025" report has been added to offering. This report provides an overview of the construction & real estate sector globally. It explores all the main active brands in the sector as well as details the movement in the sector over the last few years in the sports sponsorship the construction and real estate sector, soccer commands the top position in terms of annual sponsorship revenue and deal volume in 2025. Soccer represents approximately 60% of the total deal volume and 53% of the annual sponsorship deal value across the sector. In the construction and real estate sector, team agreements represent approximately 61% of the annual sponsorship revenue, totalling 1,416 current deals in 2025. Upon evaluating the annual deal value and the volume of transactions for each product, it is evident that series partnerships command the highest average deal value, estimated at approximately $1.77 million. The largest partnership across the construction and real estate sector in terms of annual value is FIFA's partnership with Wanda Group. Three teams which compete in the Saudi Pro League, Al Nassr FC, Al Ittihad, and Al Ahli Saudi FC, all have partnership with construction and real estate brands which are inside the top 10 largest deals across the sector. The Saudi Professional League holds the third-largest partnership in the industry through its title sponsorship deal with Roshn. Outside of the Saudi Pro League, the next largest deal across the construction and real estate sector is World Marathon Majors partnership with Wanda Group. Mitsui Fudosan is recognized as the most active brand across the construction and real estate sector, boasting 11 active partnerships in 2025. Wanda Group is recognized as the largest investor in construction and real estate within the sports industry in 2025, according to the analyst. It is important to mention that Wanda Group are involved in other industries however for the purpose of this report, their sponsorship spend is solely construction and real estate related. Roshn, the real estate firm, is the second-largest spending brand in the construction and real estate sector. European-based construction and real estate brands lead the sector in both activity and expenditure, with 986 deals to their credit, worth a collective $256.74 million annually. Reasons to Buy For those wanting an in-depth analysis of how the construction & real estate sector globally performed in the sports sponsorship industry, in the sense of both business and popularity. Key Topics Covered: 1. Key Information and Background Executive Summary Introduction 2. Market Insights Sponsorship market trends 3. Sector Analysis Sector Analysis Summary Top Sports by Value and Volume Product Category Breakdown Key Product Sponsorship Markets Top 10 Largest Deals 4. Case Study Roshn and Saudi Professional League 5. Brand Analysis Brand Analysis Summary Spend per Brand Location Top 10 Most Active Brands and Biggest Spenders Featured Brands Analysis 6. Appendix A selection of companies mentioned in this report includes, but is not limited to: Mitsui Fudosan Hormann Arena Group Aldar Saint-Gobain United Rentals Mapei Astral Pipes Soudal Wanda Group Roshn KAFD Jeddah Central Red Sea Global Al Balad Development Company Komatsu Foundation Building Materials Sobha Reality For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Metropolis Japan
3 days ago
- Business
- Metropolis Japan
Shop, Stroll and Snack at Aichi's First Full-Scale Outlet Mall
Mitsui Fudosan has announced that its latest large-scale commercial development, Mitsui Outlet Park Okazaki , will open in Okazaki City, Aichi Prefecture in November 2025. Marking Aichi's first full-scale outlet mall, the facility will include approximately 180 stores, combining outlet shopping with food, greenery and leisure. Explore more in and around Aichi with our travel guides to Chubu. The facility will be divided into two main areas: an outlet zone with around 160 stores and OKAZAKI MARKET , a park-style area with 20 additional shops. Retailers in the outlet zone will range from international fashion and sportswear brands to outdoor gear, kids' stores, and pet-related boutiques. The complex will also offer childcare services and family-friendly amenities such as a central kids' zone and an indoor play area. OKAZAKI MARKET will focus on local cuisine and regional products, with a 4,000㎡ open plaza at its core. The area will host a dog run, children's play space, and an event stage, reinforcing the development's role as a local lifestyle destination. Vendors will include leading Aichi-based shops such as Saijoen's matcha café, and long-established food retailers like Yamasa Chikuwa and Unagi Mikawa Sansuitei. Located within walking distance of Meitetsu's Honjuku Station, the development offers convenient access to major roads including National Route 1, the Shin-Tomei Expressway (Okazaki Higashi IC), and the Tomei Expressway (Otowa-Gamagori IC). The location has been designed to attract not only local residents, but also visitors from surrounding prefectures. With its mix of international brands, regional cuisine, family-friendly design, and easy access, Mitsui Outlet Park Okazaki is set to become a new commercial and cultural hub for the region when it opens in November 2025.
Yahoo
7 days ago
- Business
- Yahoo
Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
Integrated, automated facility will unlock next-generation, commercial-scale cell therapy manufacturing in Japan IDMO Smart Factory manufacturing capabilities will accelerate patient access for CAR-T and other cell therapies in the region SOUTH SAN FRANCISCO, Calif. & TOKYO, May 29, 2025--(BUSINESS WIRE)--Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan's first next-gen commercial production site for CAR-T cell therapies. The facility is under construction in Kashiwa City, a vibrant urban center located approximately 30 kilometers northeast of central Tokyo in Chiba Prefecture. As part of the extensive Tokyo metropolitan region, Kashiwa serves as a booming biotech hub. This groundbreaking Integrated Development and Manufacturing Organization (IDMO) Smart Factory is expected to provide employment to 350 people while enabling scalable and cost-effective cell therapy manufacturing, addressing an urgent need for patients in Japan and neighboring regions. The facility, set to open in partnership with Mitsui Fudosan, will utilize Cellares' state-of-the-art technology platforms, the Cell Shuttle™ and Cell Q™, to automate cell therapy manufacturing and quality control. The technology reduces batch prices by up to 50% and eliminates the manufacturing bottlenecks faced by conventional CDMOs that use manual processes. Additionally, the entire Smart Factory will be integrated and optimized to eliminate any downstream bottlenecks as well. "Cellares' new facility in Kashiwa City will enable our pharma clients to supply Japan from Japan. Manufacturing cell therapies locally simplifies cold chain logistics, accelerates vein-to-vein time and reduces cost," said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. "Our Japanese IDMO Smart Factory is part of a broader strategy to be a global manufacturing partner for our clients and meet the total patient demand for cell therapies around the world." The new site's impact extends beyond patient care. By accelerating the availability of CAR-T treatments, this initiative has the potential to help advance the development and approval of CAR-T therapeutics in Japan. Once the IDMO Smart Factory is online, technical transfers between Cellares facilities in other regions are expected to be a seamless, rapid, software-enabled process. Thanks to fully automated processes on standardized technologies, tech transfer can now happen at digital speed. Dr. Toshihiko Doi, the Chairperson of the Kashiwa-no-ha Life Science Committee, shared, "For cancer patients in Japan, the establishment of this facility provides access to cutting-edge therapies that can make a critical difference in their fight against diseases. It marks a significant step toward eliminating the drug delivery lag time that has been a challenge for rare disease and oncology treatments." Mitsui Fudosan's robust network in Japan's life sciences industry has been instrumental in enabling this collaboration, ensuring the smooth dissemination of information to the pharmaceutical industry, government agencies, and the broader healthcare community. This announcement represents Cellares' commitment to expanding its footprint in Japan, paving the way for further collaborations and innovations. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares' Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories, with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit About Mitsui Fudosan Co. Mitsui Fudosan is working to create new industries during this time of change in society and the economy. As a "Platformer," the company provides "Places" and "Communities" that bring together the ideas of companies, society, and individuals. In April 2024, it launched a Group's New Long-Term Vision, setting a strategy to explore areas beyond real estate. To support this, Innovation Promoting Division was established to drive innovation and help create new industries. At Kashiwa-no-ha Smart City, Mitsui Fudosan works with the public, private, and academic sectors to create a community where people can live healthy lives and where new life science industries can grow. View source version on Contacts Cellares ContactsInvestors:ir@ Media:pr@ Sign in to access your portfolio
Business Wire
7 days ago
- Business
- Business Wire
Cellares and Mitsui Fudosan Announce the First IDMO Smart Factory for Commercial-Scale Cell Therapy Manufacturing in Japan
SOUTH SAN FRANCISCO, Calif. & TOKYO--(BUSINESS WIRE)-- Cellares, a pioneer in automated cell therapy manufacturing, in collaboration with Mitsui Fudosan, announces the establishment of Japan's first next-gen commercial production site for CAR-T cell therapies. The facility is under construction in Kashiwa City, a vibrant urban center located approximately 30 kilometers northeast of central Tokyo in Chiba Prefecture. As part of the extensive Tokyo metropolitan region, Kashiwa serves as a booming biotech hub. This groundbreaking Integrated Development and Manufacturing Organization (IDMO) Smart Factory is expected to provide employment to 350 people while enabling scalable and cost-effective cell therapy manufacturing, addressing an urgent need for patients in Japan and neighboring regions. The facility, set to open in partnership with Mitsui Fudosan, will utilize Cellares' state-of-the-art technology platforms, the Cell Shuttle™ and Cell Q™, to automate cell therapy manufacturing and quality control. The technology reduces batch prices by up to 50% and eliminates the manufacturing bottlenecks faced by conventional CDMOs that use manual processes. Additionally, the entire Smart Factory will be integrated and optimized to eliminate any downstream bottlenecks as well. 'Cellares' new facility in Kashiwa City will enable our pharma clients to supply Japan from Japan. Manufacturing cell therapies locally simplifies cold chain logistics, accelerates vein-to-vein time and reduces cost,' said Fabian Gerlinghaus, CEO and Co-Founder of Cellares. 'Our Japanese IDMO Smart Factory is part of a broader strategy to be a global manufacturing partner for our clients and meet the total patient demand for cell therapies around the world.' The new site's impact extends beyond patient care. By accelerating the availability of CAR-T treatments, this initiative has the potential to help advance the development and approval of CAR-T therapeutics in Japan. Once the IDMO Smart Factory is online, technical transfers between Cellares facilities in other regions are expected to be a seamless, rapid, software-enabled process. Thanks to fully automated processes on standardized technologies, tech transfer can now happen at digital speed. Dr. Toshihiko Doi, the Chairperson of the Kashiwa-no-ha Life Science Committee, shared, 'For cancer patients in Japan, the establishment of this facility provides access to cutting-edge therapies that can make a critical difference in their fight against diseases. It marks a significant step toward eliminating the drug delivery lag time that has been a challenge for rare disease and oncology treatments.' Mitsui Fudosan's robust network in Japan's life sciences industry has been instrumental in enabling this collaboration, ensuring the smooth dissemination of information to the pharmaceutical industry, government agencies, and the broader healthcare community. This announcement represents Cellares' commitment to expanding its footprint in Japan, paving the way for further collaborations and innovations. For more information, visit About Cellares Cellares is the first Integrated Development and Manufacturing Organization (IDMO) and takes an Industry 4.0 approach to mass manufacturing the living drugs of the 21st century. The company is developing and operating integrated technologies for cell therapy manufacturing to accelerate access to life-saving cell therapies. The company's Cell Shuttle™ integrates all the technologies required for the entire manufacturing process in a flexible and high-throughput platform that delivers end-to-end automation. While the Cell Shuttle automates cell therapy manufacturing, the Cell Q™ automates quality control at high throughput, both for in-process and release QC. Cell Shuttles™ and Cell Qs™ will be deployed in Cellares' Smart Factories around the world, enabling each Smart Factory to produce 10 times as many cell therapy batches as a conventional CDMO with the same facility size and headcount. Partnering with Cellares enables academic medical centers, biotechnology companies, and pharmaceutical companies to accelerate cell therapy development and scale out manufacturing, lower process failure rates, lower manufacturing costs, and meet global patient demand. The company is headquartered in South San Francisco, California with its first commercial-scale IDMO Smart Factory in Bridgewater, New Jersey. Cellares is building a global network of IDMO Smart Factories, with additional facilities under construction in Europe and Japan. The company is backed by world-class investors and has raised over $355 million in financing. For more information about Cellares, please visit About Mitsui Fudosan Co. Mitsui Fudosan is working to create new industries during this time of change in society and the economy. As a "Platformer," the company provides "Places" and "Communities" that bring together the ideas of companies, society, and individuals. In April 2024, it launched a Group's New Long-Term Vision, setting a strategy to explore areas beyond real estate. To support this, Innovation Promoting Division was established to drive innovation and help create new industries. At Kashiwa-no-ha Smart City, Mitsui Fudosan works with the public, private, and academic sectors to create a community where people can live healthy lives and where new life science industries can grow.
Bloomberg
23-05-2025
- Business
- Bloomberg
Borrowers Rush to Sell Yen Bonds as Rising Yields Lure Investors
Borrowers are finding a silver lining in this week's surge in Japanese bond yields with higher rates attracting credit investors. At least 10 issuers including drinks producers Kirin Holdings Co. and Suntory Holdings Ltd., as well as real estate company Mitsui Fudosan Co. and the Republic of Indonesia rushed to the market Friday. They priced more than ¥530 billion ($3.7 billion) of bonds in total, with maturities of mainly 10 years or less, in one of the busiest days this year.
